316 related articles for article (PubMed ID: 1322237)
1. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
4. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
6. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
7. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
8. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
10. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
12. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
13. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
15. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer].
Zhang J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779
[TBL] [Abstract][Full Text] [Related]
17. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
19. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
20. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
